Dr. Wes Van Voorhis, Director of CERID, recently reflected on some exciting developments within CERID.
January 29, 2019
CERID Researchers published in The Journal of Infectious Diseases: "Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis."
December 18, 2018
Researchers explore the latest advances in Cryptosporidium research at Tufts University.
October 31, 2018
Dr. Wes Van Voorhis is conducting a Phase 2A, clinical trial on the safety, tolerability, pharmacokinetics and efficacy of clofazimine in Cryptosporidiosis.